Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.11
  • Today's Change-0.13 / -4.01%
  • Shares traded6.00
  • 1 Year change-65.41%
  • Beta1.8801
Data delayed at least 15 minutes, as of May 25 2022 20:57 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. It is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). It has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

  • Revenue in USD (TTM)0.00
  • Net income in USD-35.87m
  • Incorporated2004
  • Employees12.00
  • Location
    Eledon Pharmaceuticals Inc19900 Macarthur Blvd Ste 550IRVINE 92612-8426United StatesUSA
  • Phone+1 (949) 238-8090
  • Fax+1 (302) 655-5049
  • Websitehttps://eledon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Terns Pharmaceuticals Inc1.00m-50.59m38.42m41.00--0.2583--38.42-2.01-2.010.03975.890.0056----24,390.24-28.43---29.64-------5,059.40------0.00-------70.88------
enVVeno Medical Corp0.00-19.08m39.02m24.00--0.7603-----1.82-1.820.005.420.00----0.00-38.45-109.37-39.70-164.49-------8,458.02----0.00-------69.64---0.3086--
Global Internet of People Inc22.12m8.40m41.21m96.004.730.68074.041.860.35540.35540.95562.470.50011.702.19230,381.0018.76--20.11--80.31--37.51--17.7213.40----29.32--24.02------
Evaxion Biotech A/S - ADR0.00-24.53m41.77m61.00--1.29-----1.29-
Connect Biopharma Holdings Ltd (ADR)-100.00bn-100.00bn42.41m108.00-----------------------------------------------------67.71------
Neximmune Inc0.00-57.38m42.71m74.00--0.6068-----2.53-2.530.003.080.00----0.00-56.01---59.86--------------0.00-------54.70------
Eledon Pharmaceuticals Inc0.00-35.87m42.78m12.00--0.2737-----2.44-2.440.0011.360.00----0.00-20.32-29.03-20.74-30.02------------0.00-------51.27------
Psycheceutical Bioscience Inc1.16m-149.52k42.90m28.00--0.7646--37.08-0.1157-0.11570.89530.33990.630898.602.3441,318.93-8.15-19.61-29.82-55.3660.5039.98-12.92-43.930.959--0.0906---30.5283.3743.79------
Synaptogenix Inc0.00-12.73m43.45m4.00--1.37-----2.15-
Syros Pharmaceuticals Inc24.13m-97.48m43.62m124.00--0.6951--1.81-1.55-1.550.38330.99910.1169--8.31194,580.60-47.24-52.85-54.49-62.36-----404.00-828.85----0.3936--55.62136.57-3.00---11.72--
Mink Therapeutics Inc0.00-34.14m43.96m33.00--2.54-----1.73-1.730.000.5157------0.00-------------------1.840.00-------86.05------
Avalon Globocare Corp1.40m-8.79m44.89m5.00--34.92--32.09-0.1021-0.10210.01620.01450.1335--41.42279,764.00-83.94-96.37-139.78-126.2830.0825.60-628.67-746.84---34.640.7168--0.958817.6728.31---47.54--
Sera Prognostics Inc107.00k-40.86m45.78m115.00--0.3595--427.88-1.34-1.340.00354.120.0011--4.55930.43-41.35---43.71--51.40---38,185.05-----186.860.0083--228.00---76.39------
Team, Inc.898.51m-184.19m47.00m5.20k--1.74--0.0523-5.75-5.7527.490.62781.2418.424.41172,790.60-25.37-13.47-32.81-15.9925.1326.59-20.50-11.801.83-0.70870.944--2.58-6.0823.91---17.41--
Data as of May 25 2022. Currency figures normalised to Eledon Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

47.10%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 31 Mar 20222.33m16.26%
Cormorant Asset Management LPas of 31 Mar 20221.31m9.12%
The Vanguard Group, Inc.as of 31 Mar 2022674.21k4.71%
Woodline Partners LPas of 31 Mar 2022673.14k4.71%
Point72 Asset Management LPas of 31 Mar 2022555.90k3.89%
Medical Strategy GmbHas of 31 Jan 2022375.60k2.63%
Ikarian Capital LLCas of 31 Mar 2022362.54k2.53%
CM Management LLCas of 31 Mar 2022225.00k1.57%
Geode Capital Management LLCas of 31 Mar 2022126.71k0.89%
Eversept Partners LPas of 31 Mar 2022114.01k0.80%
More ▼
Data from 31 Jan 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.